Infographic: Adalimumab Approvals in the United States and European Union

Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union. 
The Center for Biosimilars Staff
September 03, 2017
Competition for the $16 billion market for Humira is heating up with new approvals for adalimumab biosimilars in the United States and European Union. 

infographic detailing humira biosimilars approved in the US and EU

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.